TrialBlood advances2024

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.

Gail J Roboz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.